ES2318406T3 - Formulaciones utiles en el tratamiento de la impotencia masculina y femenina. - Google Patents
Formulaciones utiles en el tratamiento de la impotencia masculina y femenina. Download PDFInfo
- Publication number
- ES2318406T3 ES2318406T3 ES05025315T ES05025315T ES2318406T3 ES 2318406 T3 ES2318406 T3 ES 2318406T3 ES 05025315 T ES05025315 T ES 05025315T ES 05025315 T ES05025315 T ES 05025315T ES 2318406 T3 ES2318406 T3 ES 2318406T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- male
- impotence
- useful formulations
- female
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title claims description 8
- 201000001881 impotence Diseases 0.000 title description 10
- 239000000203 mixture Substances 0.000 title description 6
- 239000000284 extract Substances 0.000 claims abstract description 5
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 claims abstract description 4
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims abstract description 4
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 claims abstract description 4
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 4
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 4
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229940117916 cinnamic aldehyde Drugs 0.000 claims abstract description 4
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 claims abstract description 4
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 claims abstract description 4
- 229930003944 flavone Natural products 0.000 claims abstract description 4
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 4
- 235000011949 flavones Nutrition 0.000 claims abstract description 4
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 claims abstract description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 240000000143 Turnera diffusa Species 0.000 claims abstract 3
- 235000009206 Turnera diffusa Nutrition 0.000 claims abstract 3
- 235000004952 turnera diffusa Nutrition 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010057671 Female sexual dysfunction Diseases 0.000 claims description 2
- 206010057672 Male sexual dysfunction Diseases 0.000 claims description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 231100000872 sexual dysfunction Toxicity 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- CJCOBMTYEDBBSY-UHFFFAOYSA-N 2-phenoxybenzamide Chemical compound NC(=O)C1=CC=CC=C1OC1=CC=CC=C1 CJCOBMTYEDBBSY-UHFFFAOYSA-N 0.000 description 1
- 206010002652 Anorgasmia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000021663 Female sexual arousal disease Diseases 0.000 description 1
- 208000030663 Libido disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
- 241000190079 Turnera Species 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000003029 clitoris Anatomy 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940068797 tribulus terrestris extract Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Composiciones farmacéuticas que contienen dioscina, un extracto lipófilo de Turnera diffusa, flavona dimérica de Ginkgo biloba, y aldehído cinámico.
Description
Formulaciones útiles en el tratamiento de la
impotencia masculina y femenina.
La presente invención se refiere a formulaciones
que son útiles en el tratamiento de disfunciones sexuales
masculinas y femeninas.
Las disfunciones sexuales tienen una importancia
considerable y son objeto de esfuerzos intensivos en el campo de la
investigación biomédica. Según estadísticas recientes, el problema
de la impotencia en sus diversas formas (la ausencia de líbido y
las disfunciones eréctiles) afecta a alrededor del 70% de la
población con edades de aproximadamente 50 años y superiores.
Obviamente, el grado de impotencia en sus diversas formas varía en
cuanto a su gravedad, especialmente entre los ancianos, en los que,
frecuentemente, está fisiológicamente asociado con otros trastornos
tales como la enfermedad cardíaca o renal.
Los fármacos actualmente disponibles para tratar
tales disfunciones, especialmente la disfunción eréctil, incluyen
hormonas tales como la testosterona, el PIV, los derivados de
prostaglandina (PGE) y agentes cardiovasculares tales como la
papaverina, la fenoxibenzamida y la fentolamina.
Sin embargo, ninguno de estos fármacos
proporciona una solución satisfactoria y permanente del problema,
debido a los efectos secundarios que provocan y a la necesidad de
una inyección intercavernosa o intrauretral en el caso de la
papaverina y la PEG_{2}, por ejemplo.
Recientemente, se han desarrollado inhibidores
de la fosfodiesterasa degradante del GMPc que son particularmente
útiles en el tratamiento de la impotencia, y se activan por vía
oral. Uno de estos agentes, denominado Sildenafil (documento WO
94/28902), ya está en el mercado.
Sin embargo, de nuevo, lo efectos secundarios no
son nada desdeñables, siendo la necesidad de tratamientos más
seguros y más eficaces una consideración ampliamente extendida.
La Farmacología moderna está estudiando ahora
numerosos productos de origen natural (principalmente de base
vegetal, pero también animal) en base a las indicaciones obtenidas
de la medicina tradicional para evaluar la posible base científica
para su uso empírico.
Los estudios bioquímicos han demostrado la gran
complejidad de los mecanismos que participan en los procesos
fisiológicos asociados con la actividad sexual, tales como la
erección del pene y del clítoris, la lubricación vaginal, la
eyaculación y el orgasmo.
Mediadores tales como el óxido nítrico (NO), los
factores enzimáticos que participan en el metabolismo de los
mensajeros AMPc y GMPc, los receptores adrenérgicos de las membranas
celulares del músculo liso, los neurotransmisores dopaminérgicos y
los receptores de las PGE u otras hormonas son las posibles dianas
de un tratamiento farmacológico para la impotencia y otras
disfunciones sexuales.
Obviamente, resulta difícil proporcionar una
solución satisfactoria a este problema específico, en parte porque,
además de los aspectos puramente bioquímicos y fisiológicos, también
hay factores ambientales y psicológicos que pueden complicar aún
más el cuadro clínico de los pacientes que padecen trastornos
sexuales.
Ahora se ha descubierto que una combinación de
extractos de plantas medicinales con propiedades específicas, en
ciertas proporciones cuantitativas, proporciona resultados
terapéuticos particularmente satisfactorios en el tratamiento de
las disfunciones sexuales masculinas y femeninas.
La invención se refiere en particular al uso de
dioscina, flavona dimérica del Ginkgo biloba y aldehído
cinámico en combinación con un extracto lipófilo de Turnera
difusa para la preparación de un medicamento para el
tratamiento de impotencia, disfunción eréctil, los trastornos de
libido, la frigidez y la anorgasmia así como los medicamentos que
comprenden dicha combinación.
La administración crónica de las composiciones
de la invención no causa ningún efecto secundario significativo, se
tolera bien y no altera los delicados equilibrios hormonales,
especialmente, el equilibrio andrógeno/estrógeno que gobiernan los
episodios fisiológicos principales en hombres y en mujeres tales
como la andropausia y la menopausia.
Los ejemplos de formas adecuadas de
administración de las composiciones de la invención incluyen
comprimidos, cápsulas de gelatina blanda y dura, supositorios y
preparaciones bebibles que contienen dosis unitarias de entre 100 y
300 mg de extracto de Tribulus terrestris, y dosis unitarias
del resto de los componentes según las proporciones en peso
anteriormente especificadas. Las formulaciones en fase sólida tales
como los comprimidos gastrorresistentes o de liberación no
modificada, o las formas líquidas bebibles son particularmente
preferidos.
Claims (2)
1. Composiciones farmacéuticas que contienen
dioscina, un extracto lipófilo de Turnera diffusa, flavona
dimérica de Ginkgo biloba, y aldehído cinámico.
2. El uso de dioscina un extracto lipófilo de
Turnera diffusa, flavona dimérica de Ginkgo biloba, y
aldehído cinámico para la preparación de un medicamento para el
tratamiento de disfunciones sexuales masculinas y femeninas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI02A0990 | 2002-05-10 | ||
IT2002MI000990A ITMI20020990A1 (it) | 2002-05-10 | 2002-05-10 | Formulazioni utili nel trattamento dell'impotenza maschile e femminile |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2318406T3 true ES2318406T3 (es) | 2009-05-01 |
Family
ID=11449866
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES05025315T Expired - Lifetime ES2318406T3 (es) | 2002-05-10 | 2003-04-30 | Formulaciones utiles en el tratamiento de la impotencia masculina y femenina. |
ES03729955T Expired - Lifetime ES2259139T3 (es) | 2002-05-10 | 2003-04-30 | Formulaciones utiles en el tratamiento de la impotencia masculina y femenina. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES03729955T Expired - Lifetime ES2259139T3 (es) | 2002-05-10 | 2003-04-30 | Formulaciones utiles en el tratamiento de la impotencia masculina y femenina. |
Country Status (19)
Country | Link |
---|---|
US (1) | US7128932B2 (es) |
EP (2) | EP1658854B1 (es) |
JP (1) | JP4603351B2 (es) |
KR (1) | KR20040102212A (es) |
CN (2) | CN101164559A (es) |
AT (2) | ATE319466T1 (es) |
AU (1) | AU2003240478B8 (es) |
CA (1) | CA2485264A1 (es) |
DE (2) | DE60303925T2 (es) |
DK (2) | DK1658854T3 (es) |
ES (2) | ES2318406T3 (es) |
HK (1) | HK1085374A1 (es) |
IL (2) | IL165081A (es) |
IT (1) | ITMI20020990A1 (es) |
NO (2) | NO332805B1 (es) |
PT (2) | PT1658854E (es) |
RU (2) | RU2313357C2 (es) |
SI (2) | SI1503775T1 (es) |
WO (1) | WO2003094943A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6952691B2 (en) * | 2002-02-01 | 2005-10-04 | International Business Machines Corporation | Method and system for searching a multi-lingual database |
CA2541578C (en) * | 2003-10-10 | 2014-03-25 | Ethypharm | Sustained-release microgranules containing gingko biloba extract and the process for manufacturing these |
WO2006021930A2 (en) * | 2004-08-25 | 2006-03-02 | Femi-X A/S | Aphrodisiac herbal composition for a female comprising epimedium grandiflorum, turnera diffusa var. aphrodisiaca, ilex paraguariensis and smilax spp |
KR100660116B1 (ko) * | 2005-01-26 | 2006-12-20 | (주)포메디 | 홍삼 및 대두를 주성분으로 포함하는 복합 한방 제제를유효성분으로 함유하는 성기능 개선용 조성물 |
WO2006111830A2 (en) * | 2005-04-20 | 2006-10-26 | Council Of Scientific And Industrial Research | Functional aphrodisiac rolled herbal bidis and cigarettes |
EP1932531A1 (de) * | 2006-12-11 | 2008-06-18 | Finzelberg GmbH & Co. KG | Spezialextrakt und seine Verwendung zur Hemmung des Abbaus von cyclischem Guanosinmonophosphat (cGMP) |
US8362088B2 (en) * | 2006-12-14 | 2013-01-29 | Warnock W Matthew | Method and article of manufacture for encapsulating a homeopathic ingredient with a second ingredient |
US9918489B2 (en) * | 2008-12-17 | 2018-03-20 | Mark Gorris | Food-based supplement delivery system |
US20100178413A1 (en) * | 2008-12-17 | 2010-07-15 | Mark Gorris | Food-based Supplement Delivery System |
US8609155B2 (en) * | 2009-09-17 | 2013-12-17 | Tradapharma Sagl | Dietary supplement stimulating the male sexual function |
ES2386859B1 (es) * | 2011-02-07 | 2013-03-22 | Eduardo Antonio Gómez De Diego | Composición natural para aumentar el vigor. |
RU2458537C1 (ru) * | 2011-03-14 | 2012-08-20 | Общество С Ограниченной Ответственностью "Парафарм" | Биологически активная добавка к пище для профилактики эректильной дисфункции у мужчин |
ITLI20110007A1 (it) * | 2011-09-10 | 2013-03-11 | Lloyds Internat Credit Llc | Una innovativa composizione naturale efficace per la cura dell'impotenza |
TW201420745A (zh) * | 2012-11-26 | 2014-06-01 | Tian-De Li | 擴充男性海綿體的複方精油 |
US10226418B2 (en) | 2014-05-12 | 2019-03-12 | Susie Q, Ltd. | Arginine-containing topical composition |
US10016477B1 (en) | 2015-01-13 | 2018-07-10 | Roger Yomba Ngue | Natural composition |
IT201700115753A1 (it) * | 2017-10-13 | 2019-04-13 | Cristalfarma S R L | Integratore per attenuare i disturbi nella donna causati dall’invecchiamento |
EP3560488A1 (en) * | 2018-04-24 | 2019-10-30 | Procare Health Iberia, S.L. | Compositions for treating female sexual dysfunction |
WO2022027122A1 (en) * | 2020-08-06 | 2022-02-10 | Ramade & Cia Holding Corp. | Compositions with cannabinoids of cannabis sativa for treating erectile and sexual dysfunction |
IT202100031175A1 (it) * | 2021-12-13 | 2023-06-13 | Anvest Group S R L | Composizione per il trattamento della disfunzione erettile |
GR1010519B (el) * | 2022-07-04 | 2023-08-10 | Νικολαος Τυμπανιδης | Καταπινομενο σκευασμα για τονωση της ζωτικοτητας, της αντοχης και της γενικοτερης ευεξιας των ανδρων |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1084746A (zh) * | 1992-11-25 | 1994-04-06 | 王立本 | 防治性病的特效***液及其制作方法 |
AU674602B2 (en) * | 1993-09-14 | 1997-01-02 | Hyung Ki Choi | Pharmaceutical composition for prophylaxis and treatment of premature ejaculation |
IT1269634B (it) * | 1994-05-06 | 1997-04-08 | Indena Spa | Medicamento topico ad attivita' cicatrizzante |
CN1141185A (zh) * | 1996-02-16 | 1997-01-29 | 范凯 | 保健药酒 |
FR2765483B1 (fr) * | 1997-07-04 | 2000-02-04 | Philippe Gorny | Medicament destine a traiter les dysfonctions erectiles |
US6007824A (en) * | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
AU744508B2 (en) * | 1998-08-03 | 2002-02-28 | Ronald E. Wheeler | Prostate formula |
CA2414094A1 (en) * | 1999-05-27 | 2000-12-07 | Armadillo Pharmaceuticals, Inc. | Pharmaceutical preparations of bioactive substances extracted from natural sources |
RU2153347C1 (ru) * | 1999-06-04 | 2000-07-27 | Общество с ограниченной ответственностью "Доктор Н" | Гомеопатическое лекарственное средство для лечения импотенции |
US6803060B2 (en) * | 2000-09-07 | 2004-10-12 | Joe Reyes | Composition to boost libido |
US6444237B1 (en) * | 2001-09-13 | 2002-09-03 | Pamela A. Heleen | Herbal composition for enhancing sexual response |
WO2003028747A1 (en) * | 2001-10-04 | 2003-04-10 | Harris Dennis H | Ingestible nerve and circulatory nutritional formulation |
-
2002
- 2002-05-10 IT IT2002MI000990A patent/ITMI20020990A1/it unknown
-
2003
- 2003-04-30 PT PT05025315T patent/PT1658854E/pt unknown
- 2003-04-30 AU AU2003240478A patent/AU2003240478B8/en not_active Ceased
- 2003-04-30 DE DE60303925T patent/DE60303925T2/de not_active Expired - Lifetime
- 2003-04-30 DK DK05025315T patent/DK1658854T3/da active
- 2003-04-30 CN CNA2007101849612A patent/CN101164559A/zh active Pending
- 2003-04-30 EP EP05025315A patent/EP1658854B1/en not_active Expired - Lifetime
- 2003-04-30 SI SI200330200T patent/SI1503775T1/sl unknown
- 2003-04-30 EP EP03729955A patent/EP1503775B1/en not_active Expired - Lifetime
- 2003-04-30 US US10/513,730 patent/US7128932B2/en not_active Expired - Fee Related
- 2003-04-30 JP JP2004503026A patent/JP4603351B2/ja not_active Expired - Fee Related
- 2003-04-30 AT AT03729955T patent/ATE319466T1/de active
- 2003-04-30 SI SI200331496T patent/SI1658854T1/sl unknown
- 2003-04-30 ES ES05025315T patent/ES2318406T3/es not_active Expired - Lifetime
- 2003-04-30 DE DE60325657T patent/DE60325657D1/de not_active Expired - Lifetime
- 2003-04-30 CA CA002485264A patent/CA2485264A1/en not_active Abandoned
- 2003-04-30 AT AT05025315T patent/ATE418995T1/de active
- 2003-04-30 ES ES03729955T patent/ES2259139T3/es not_active Expired - Lifetime
- 2003-04-30 RU RU2004132833/15A patent/RU2313357C2/ru not_active IP Right Cessation
- 2003-04-30 PT PT03729955T patent/PT1503775E/pt unknown
- 2003-04-30 CN CNB038103842A patent/CN100356935C/zh not_active Expired - Fee Related
- 2003-04-30 DK DK03729955T patent/DK1503775T3/da active
- 2003-04-30 WO PCT/EP2003/004528 patent/WO2003094943A1/en active IP Right Grant
- 2003-04-30 KR KR10-2004-7017861A patent/KR20040102212A/ko active Search and Examination
-
2004
- 2004-11-08 IL IL165081A patent/IL165081A/en not_active IP Right Cessation
- 2004-11-22 NO NO20044855A patent/NO332805B1/no not_active IP Right Cessation
-
2005
- 2005-09-16 HK HK05108114A patent/HK1085374A1/xx not_active IP Right Cessation
-
2007
- 2007-03-07 RU RU2007108559/15A patent/RU2440127C2/ru not_active IP Right Cessation
-
2008
- 2008-06-12 IL IL192138A patent/IL192138A/en not_active IP Right Cessation
-
2012
- 2012-05-25 NO NO20120620A patent/NO20120620L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2318406T3 (es) | Formulaciones utiles en el tratamiento de la impotencia masculina y femenina. | |
ES2297593T3 (es) | Formulaciones utiles en el tratamiento de la impotencia masculina y femenina. | |
US20090092687A1 (en) | Prhormone composition and method of use thereof | |
KR20140020232A (ko) | 발기 부전 치료를 위한 조성물 및 방법 | |
BRPI0614434A2 (pt) | composições compreendendo um doador de no e um ditiolano e o uso das mesmas para o melhoramento da função sexual | |
WO2022027122A1 (en) | Compositions with cannabinoids of cannabis sativa for treating erectile and sexual dysfunction | |
PL203555B1 (pl) | Kompozycje farmaceutyczne zawieraj ace ekstrakty Tribulus terrestris, Turnera diffusa, Cinnamon cassia i ekstrakt z Ginkgo biloba oraz ich zastosowanie do wytwarzania leku do leczenia m eskiej i ze nskiej impotencji |